518
Participants
Start Date
April 21, 2015
Primary Completion Date
September 16, 2016
Study Completion Date
May 25, 2023
DTG 50 mg
Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
RPV 25 mg
"Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV."
CAR
CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
GSK Investigational Site, New Taipei City
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Kaohsiung City
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Rosario
GSK Investigational Site, Darlinghurst
GSK Investigational Site, Sydney
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Marseille
GSK Investigational Site, Buffalo
GSK Investigational Site, A Coruña
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Milan
GSK Investigational Site, Bergamo
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Móstoles
GSK Investigational Site, Murcia
GSK Investigational Site, Cartagena
GSK Investigational Site, Hanover
GSK Investigational Site, Macon
GSK Investigational Site, Vero Beach
GSK Investigational Site, Bordeaux
GSK Investigational Site, Oviedo
GSK Investigational Site, Fort Lauderdale
GSK Investigational Site, West Palm Beach
GSK Investigational Site, Santa Cruz La Laguna
GSK Investigational Site, Taichung
GSK Investigational Site, Valencia
GSK Investigational Site, Southfield
GSK Investigational Site, Cologne
GSK Investigational Site, Bonn
GSK Investigational Site, Tourcoing
GSK Investigational Site, Omaha
GSK Investigational Site, Lyon
GSK Investigational Site, Paris
GSK Investigational Site, Austin
GSK Investigational Site, Saint-Denis
GSK Investigational Site, Bakersfield
GSK Investigational Site, Seattle
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Krasnodar
GSK Investigational Site, Saratov
GSK Investigational Site, Barnaul
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Montreal
GSK Investigational Site, Montreal
GSK Investigational Site, Montreal
GSK Investigational Site, Montreal
GSK Investigational Site, Regina
GSK Investigational Site, Toronto
GSK Investigational Site, Vancouver
GSK Investigational Site, Alicante
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, London
Lead Sponsor
Collaborators (2)
Janssen Pharmaceuticals
INDUSTRY
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY